Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Choroidal Neovascularization - Overview
Choroidal Neovascularization - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Choroidal Neovascularization - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Choroidal Neovascularization - Companies Involved in Therapeutics Development
3SBio Inc
Allysta Pharmaceuticals Inc
AsclepiX Therapeutics Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Iconic Therapeutics Inc
Isar Therapeutics GmbH
Lupin Ltd
Mabion SA
NovelMed Therapeutics Inc
Oceanyx Pharmaceuticals Inc
Promedior Inc
Protheragen Inc
Yantai RC-Pharmaceutical Co Ltd
Choroidal Neovascularization - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allo-Aca - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Apratoxin S4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
faricimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Calreticulin for Choroidal Neovascularization - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICON-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0036 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit SCG3 for Metabolic Disorders, Oncology and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit VEGF for Ophthalmology and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-9405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RC-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Choroidal Neovascularization and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Choroidal Neovascularization - Dormant Projects
Choroidal Neovascularization - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Choroidal Neovascularization, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Choroidal Neovascularization, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Choroidal Neovascularization - Pipeline by 3SBio Inc, H2 2019
Choroidal Neovascularization - Pipeline by Allysta Pharmaceuticals Inc, H2 2019
Choroidal Neovascularization - Pipeline by AsclepiX Therapeutics Inc, H2 2019
Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Choroidal Neovascularization - Pipeline by Formycon AG, H2 2019
Choroidal Neovascularization - Pipeline by Iconic Therapeutics Inc, H2 2019
Choroidal Neovascularization - Pipeline by Isarna Therapeutics GmbH, H2 2019
Choroidal Neovascularization - Pipeline by Lupin Ltd, H2 2019
Choroidal Neovascularization - Pipeline by Mabion SA, H2 2019
Choroidal Neovascularization - Pipeline by NovelMed Therapeutics Inc, H2 2019
Choroidal Neovascularization - Pipeline by Oceanyx Pharmaceuticals Inc, H2 2019
Choroidal Neovascularization - Pipeline by Promedior Inc, H2 2019
Choroidal Neovascularization - Pipeline by Protheragen Inc, H2 2019
Choroidal Neovascularization - Pipeline by Yantai RC-Pharmaceutical Co Ltd, H2 2019
Choroidal Neovascularization - Dormant Projects, H2 2019
Choroidal Neovascularization - Dormant Projects, H2 2019 (Contd..1), H2 2019
Choroidal Neovascularization - Discontinued Products, H2 2019